De novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody
Annals of Surgical Treatment and Research
;
: 145-150, 2015.
Article
in English
| WPRIM
| ID: wpr-26224
ABSTRACT
PURPOSE:
The use of hepatitis B core antibody (HBcAb)-positive grafts is increasing, especially where hepatitis B is endemic. However, this remains controversial because of the risk of development of de novo HBV infection.METHODS:
We collected information obtained between January 2000 and December 2012 and retrospectively analyzed data on 187 HBsAg-negative donors and recipients were analyzed retrospectively. De novo HBV infection was defined as development of HBsAg positivity with or without detection of HBV DNA.RESULTS:
Forty patients (21.4%) received HBcAb-positive grafts. Survival rate did not differ by donor HBcAb status (P = 0.466). De novo HBV infection occurred in five patients (12.5%) who were not treated with anti-HBV prophylaxis, and was significantly more prevalent in hepatitis B surface antibody (HBsAb)- and HBcAb-negative than HBsAb- and HBcAb-positive recipients (50% vs. 4.2%, P = 0.049). All patients except one were treated with entecavir with/without antihepatitis B immunoglobulin and four were negative in terms of HBV DNA seroconversion. No patient died.CONCLUSION:
HBcAb-positive grafts are safe without survival difference. However, the risk of de novo hepatitis B virus infection was significantly increased in HBsAb- and HBcAb-negative recipients. All patients were successfully treated even after recurrence.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Recurrence
/
Tissue Donors
/
DNA
/
Immunoglobulins
/
Hepatitis B virus
/
Survival Rate
/
Retrospective Studies
/
Liver Transplantation
/
Transplants
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Annals of Surgical Treatment and Research
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS